CL
CLRPF.US Clarity Pharmaceuticals Ltd
- Market cap
- USD 478M
- P/E
- -
- P/B
- 4.09x
- ROE
- -57.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CLRPF.US undervalued?
Graham numberThe Graham number of Clarity Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Clarity Pharmaceuticals Ltd fundamental analysis
No fundamental analysis for Clarity Pharmaceuticals Ltd yet.
Clarity Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung ca…
Full company profileClarity Pharmaceuticals Ltd financial statements
Clarity Pharmaceuticals Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Operating Income | - | - | -30.3M | -36.2M | -56.3M | -78.6M | -119M |
| EBITDA | - | - | -30.2M | -36.1M | -56.2M | -78.4M | -119M |
| Net Income | - | - | -23.8M | -24.6M | -42.3M | -64.3M | -107M |
| EPS | - | - | -0.09 | -0.19 | -0.14 | -0.20 | -0.29 |
| Balance Sheet | |||||||
| Total Assets | - | - | 99.8M | 76.9M | 155M | 101M | 199M |
| Total Liabilities | - | - | 7.59M | 7.72M | 8.33M | 10.9M | 13.0M |
| Shareholders' Equity | - | - | 92.2M | 69.2M | 146M | 90.2M | 186M |
| Cash & Short-term Investments | - | - | 55.3M | 31.2M | 47.9M | 47.7M | 57.2M |
| Cash Flow | |||||||
| Operating Cash Flow | -6.83M | -7.68M | -13.3M | -27.5M | - | - | - |
| Capital Expenditure | 14.5K | 60.3K | 213K | 46.6K | 504K | 183K | 307K |
| Free Cash Flow | - | - | -13.5M | -27.5M | -43.7M | -55.0M | -92.9M |
| Ratios | |||||||
| ROE | - | - | -25.8% | -35.6% | -28.9% | -71.3% | -57.6% |
| ROA | - | - | -23.8% | -32.0% | -27.4% | -63.6% | -53.9% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Clarity Pharmaceuticals Ltd dividends
Clarity Pharmaceuticals Ltd has not paid dividends in the last 7 fiscal years.
Who owns Clarity Pharmaceuticals Ltd
- Insiders 21.15%
- Institutions 30.76%
- Public & others 48.10%
- Shares outstanding 373M
- Free float 289M
Clarity Pharmaceuticals Ltd company profile
- Company name
- Clarity Pharmaceuticals Ltd
- Ticker
- CLRPF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- June
- Address
- National Innovation Centre, Sydney, NSW, Australia, 2015
- Phone
- 61 2 9209 4037
- Website
- claritypharmaceuticals.com
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Clarity Pharmaceuticals Ltd management
10- Dr. Alan John Taylor Ph.D.Executive Chairman
- Ms. Michelle ParkerCEO, MD & Executive Director
- Mr. David K. Green BEc., CAChief Financial Officer
- Dr. Colin David Biggin Ph.D.Chief Operating Officer
- Dr. Ellen van Dam Ph.D.Chief Scientific Officer
- Ms. Lisa SadetskayaDirector of Corporate Communications.
- Ms. Mary BennettHead of People & Culture
- Mr. Shaemus GleasonExecutive Vice President of Operations
- Dr. Othon GervasioChief Medical Officer
- Ms. Eva LengyelovaExecutive Vice President of Clinical Development